Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

Background: In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain health...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Pharmacol
Hauptverfasser: Moorkens, Evelien, Jonker-Exler, Clara, Huys, Isabelle, Declerck, Paul, Simoens, Steven, Vulto, Arnold G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2016
Schlagworte:
Pharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4925708/
https://ncbi.nlm.nih.gov/pubmed/27445826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00193
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge